Letters to the editor
MAFLD vs. MASLD: Consensus is unlike evidence!
Enas Kamal, Alaa M Mostafa
, Yasser Fouad
Corresponding author
Department of Endemic Medicine and Gastroenterology, Faculty of Medicine, Minia University, Minia, Egypt
Read
614
Timeswas read the article
96
Total PDF
518
Total HTML
Share statistics
array:22 [ "pii" => "S1665268124003211" "issn" => "16652681" "doi" => "10.1016/j.aohep.2024.101527" "estado" => "S300" "fechaPublicacion" => "2024-09-01" "aid" => "101527" "copyrightAnyo" => "2024" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Ann Hepatol. 2024;29:" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:18 [ "pii" => "S166526812400320X" "issn" => "16652681" "doi" => "10.1016/j.aohep.2024.101526" "estado" => "S300" "fechaPublicacion" => "2024-09-01" "aid" => "101526" "copyright" => "Fundación Clínica Médica Sur, A.C." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Ann Hepatol. 2024;29:" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:8 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letters to the editor</span>" "titulo" => "NAFLD-MASLD-MAFLD continuum: A swinging pendulum?" "tienePdf" => "en" "tieneTextoCompleto" => "en" "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:6 [ 0 => array:2 [ "autoresLista" => "Mariana M. Ramírez-Mejía" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Mariana M." "apellidos" => "Ramírez-Mejía" ] ] ] 1 => array:2 [ "autoresLista" => "Xingshun Qi" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Xingshun" "apellidos" => "Qi" ] ] ] 2 => array:2 [ "autoresLista" => "Ludovico Abenavoli" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Ludovico" "apellidos" => "Abenavoli" ] ] ] 3 => array:2 [ "autoresLista" => "Beatriz Barranco-Fragoso" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Beatriz" "apellidos" => "Barranco-Fragoso" ] ] ] 4 => array:2 [ "autoresLista" => "Sandra M. Barbalho" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Sandra M." "apellidos" => "Barbalho" ] ] ] 5 => array:2 [ "autoresLista" => "Nahum Méndez-Sánchez" "autores" => array:1 [ 0 => array:2 [ "nombre" => "Nahum" "apellidos" => "Méndez-Sánchez" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S166526812400320X?idApp=UINPBA00004N" "url" => "/16652681/0000002900000005/v1_202408300521/S166526812400320X/v1_202408300521/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S1665268124003156" "issn" => "16652681" "doi" => "10.1016/j.aohep.2024.101521" "estado" => "S300" "fechaPublicacion" => "2024-09-01" "aid" => "101521" "copyright" => "Fundación Clínica Médica Sur, A.C." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Ann Hepatol. 2024;29:" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:8 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letters to the editor</span>" "titulo" => "MAFLD or MASLD: Let the evidence decide again" "tienePdf" => "en" "tieneTextoCompleto" => "en" "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Ziyan Pan, Mohammed Eslam" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Ziyan" "apellidos" => "Pan" ] 1 => array:2 [ "nombre" => "Mohammed" "apellidos" => "Eslam" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268124003156?idApp=UINPBA00004N" "url" => "/16652681/0000002900000005/v1_202408300521/S1665268124003156/v1_202408300521/en/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Letters to the editor</span>" "titulo" => "MAFLD vs. MASLD: Consensus is unlike evidence!" "tieneTextoCompleto" => true "saludo" => "To the Editor:" "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Enas Kamal, Alaa M Mostafa, Yasser Fouad" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Enas" "apellidos" => "Kamal" ] 1 => array:4 [ "nombre" => "Alaa M" "apellidos" => "Mostafa" "email" => array:1 [ 0 => "alaam.mostafa@gmail.com" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0001" ] ] ] 2 => array:2 [ "nombre" => "Yasser" "apellidos" => "Fouad" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Department of Endemic Medicine and Gastroenterology, Faculty of Medicine, Minia University, Minia, Egypt" "identificador" => "aff0001" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0001" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="para0001" class="elsevierStylePara elsevierViewall">We read with interest the study by Pan <span class="elsevierStyleItalic">et al</span>., demonstrating that metabolic dysfunction associated fatty liver disease (MAFLD) is superior to metabolic dysfunction associated steatotic liver disease (MASLD) in identifying individuals at risk of chronic kidney disease [<a class="elsevierStyleCrossRef" href="#bib0001">1</a>]. The study extends recent similar findings showed that MAFLD is better than MASLD identifying metabolic dysfunction, hepatic and extra-hepatic outcomes [<a class="elsevierStyleCrossRefs" href="#bib0002">2-4</a>].</p><p id="para0002" class="elsevierStylePara elsevierViewall">These findings beg an interesting question, why the MASLD definition, which came second after MAFLD, failed to provide a conceptual advance. Although the actual causes may be not clear, a key obvious cause is consensus is unlike evidence. The MASLD proposal is grounded on a questionnaire of personal views that might be heavily compounded by various types of conflict of interests and could be influenced by the view of few but vocal participants in this consensus process. Additionally, it is crucial to realise scientific truth is about evidence not consensus alone and in many circumstances the expert opinions turned to be not the same as evidence-based data [<a class="elsevierStyleCrossRef" href="#bib0005">5</a>]. A recent analysis of over a hundred consensus demonstrates that the rigor of statement development in consensus statements is less than one-third of that of evidence-based guidelines [<a class="elsevierStyleCrossRef" href="#bib0006">6</a>].</p><p id="para0003" class="elsevierStylePara elsevierViewall">Notably, when the metabolic dysfunction associated fatty liver disease (MAFLD) revolutionary proposal was introduced [<a class="elsevierStyleCrossRef" href="#bib0007">7</a>,<a class="elsevierStyleCrossRef" href="#bib0008">8</a>], the opponents raised multiple concerns. One of the key concerns that was raised by Moreno <span class="elsevierStyleItalic">et al.</span>, on behalf of the EASL Consortium for the Study of Alcohol-related LiVer disease in Europe (SALVE) that in a patient satisfying criteria for MAFLD but with another risk factor including alcohol intake, the term “dual-aetiology fatty liver disease” [<a class="elsevierStyleCrossRef" href="#bib0009">9</a>]. They went very heavily to suggest that this would lead to separating individuals exposed to alcohol consumption into two categories (ALD for individuals with normal weight and dual etiology fatty liver disease for overweight or obese individuals) and that patients satisfying metabolic risk criteria would no longer be recorded as having ALD. This could lead to overlooking the importance of the amount of alcohol consumption on fibrosis and the importance of reductions in alcohol consumption to outcomes and could impact the funding of alcohol research [<a class="elsevierStyleCrossRef" href="#bib0009">9</a>].</p><p id="para0004" class="elsevierStylePara elsevierViewall">However, the MAFLD proposal dealt carefully with these aspects by suggesting “dual-etiology” as a “concept” and not a “term”. This concept encompasses patients with MAFLD and ALD as well as those of MAFLD with other aetiologies as chronic hepatitis B or C. [<a class="elsevierStyleCrossRef" href="#bib0010">10</a>] However, the fundamental and logic question where these concerns went with the proposal of “metALD” that introduced an actual term not just a concept? This term separates patients with ALD, with the vast majority of ALD patients would now be labelled as MetALD.</p><p id="para0005" class="elsevierStylePara elsevierViewall">Similarly, we recently raised concerns on how the change of F to S from fatty to steatotic addressed all concerns that were raised in the popular editorial that was published raising doubts on the potential negative impact of the premature change from NAFLD to MAFLD on various aspects including epidemiology, noninvasive score performance and clinical trials [<a class="elsevierStyleCrossRef" href="#bib0011">11</a>]. It is not clear why suddenly the premature became mature [<a class="elsevierStyleCrossRef" href="#bib0012">12</a>].</p><p id="para0006" class="elsevierStylePara elsevierViewall">Another striking example, I bet every researcher in the field who submitted a manuscript over the last few years using the MAFLD term has encountered comment that “you cannot use MAFLD to describe data generated under the NAFLD term”. Therefore, again how it became not only OK but encouraged and sometimes forced to use data generated under the NAFLD term using the MASLD term.</p><p id="para0007" class="elsevierStylePara elsevierViewall">In total, “You can hide memories, but you can't erase history that produced them”. Let the evidence not opinion guide our path, as unbiased evidence is a self-fulfilling guarantee that the evidence will not be affected by conflicts of interest. More studies as the current study [<a class="elsevierStyleCrossRef" href="#bib0001">1</a>] are required to generate evidence-based recommendations.</p><span id="sec0001" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cesectitle0002">Funding</span><p id="para0008" class="elsevierStylePara elsevierViewall">There has been no kind of support for this manuscript by any source.</p></span><span id="sec0002" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="cesectitle0003">Author contribution</span><p id="para0009" class="elsevierStylePara elsevierViewall">YF and EK were involved in the conceptualization, and writing the original draft while All authors revised the original draft, added comments, and approved the final draft.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:3 [ 0 => array:2 [ "identificador" => "sec0001" "titulo" => "Funding" ] 1 => array:2 [ "identificador" => "sec0002" "titulo" => "Author contribution" ] 2 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2024-05-08" "fechaAceptado" => "2024-06-13" "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "cebibsec1" "bibliografiaReferencia" => array:12 [ 0 => array:3 [ "identificador" => "bib0001" "etiqueta" => "[1]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "Z. Pan" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Ann Hepatol" "fecha" => "2024" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0002" "etiqueta" => "[2]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The MASLD criteria overlook a number of adolescent patients with severe steatosis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "Z Pan" 1 => "M Eslam" 2 => "A Choudhury" 3 => "B Sahoo" 4 => "CR Lesmana" 5 => "FM. Sanai" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "J Hepatol" "fecha" => "2024" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0003" "etiqueta" => "[3]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "MAFLD predicts cardiovascular disease risk better than MASLD" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "Z Pan" 1 => "G Shiha" 2 => "G Esmat" 3 => "N Méndez-Sánchez" 4 => "M. Eslam" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Liver Int" "fecha" => "2024" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0004" "etiqueta" => "[4]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Breaking new ground: MASLD vs. MAFLD—which holds the key for risk stratification?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "MM Ramírez-Mejía" 1 => "C Jiménez-Gutiérrez" 2 => "M Eslam" 3 => "J George" 4 => "N. Méndez-Sánchez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12072-023-10620-y" "Revista" => array:7 [ "tituloSerie" => "Hepatol Int" "fecha" => "2024" "volumen" => "18" "numero" => "1" "paginaInicial" => "168" "paginaFinal" => "178" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/38127259" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0005" "etiqueta" => "[5]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The NAFLD-MAFLD debate: eminence vs evidence" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Y Fouad" 1 => "R Elwakil" 2 => "M Elsahhar" 3 => "E Said" 4 => "S Bazeed" 5 => "A Ali Gomaa" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/liv.14739" "Revista" => array:7 [ "tituloSerie" => "Liver Int" "fecha" => "2021" "volumen" => "41" "numero" => "2" "paginaInicial" => "255" "paginaFinal" => "260" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33220154" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0006" "etiqueta" => "[6]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical practice guidelines and consensus statements in oncology–an assessment of their methodological quality" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C Jacobs" 1 => "ID Graham" 2 => "J Makarski" 3 => "M Chasse" 4 => "D Fergusson" 5 => "B Hutton" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "PLoS One" "fecha" => "2014" "volumen" => "9" "numero" => "10" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0007" "etiqueta" => "[7]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M Eslam" 1 => "N Alkhouri" 2 => "P Vajro" 3 => "U Baumann" 4 => "R Weiss" 5 => "P Socha" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S2468-1253(21)00183-7" "Revista" => array:7 [ "tituloSerie" => "Lancet Gastroenterol Hepatol" "fecha" => "2021" "volumen" => "6" "numero" => "10" "paginaInicial" => "864" "paginaFinal" => "873" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34364544" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0008" "etiqueta" => "[8]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M Eslam" 1 => "PN Newsome" 2 => "SK Sarin" 3 => "QM Anstee" 4 => "G Targher" 5 => "M Romero-Gomez" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jhep.2020.03.039" "Revista" => array:8 [ "tituloSerie" => "J Hepatol" "fecha" => "2020" "volumen" => "73" "numero" => "1" "paginaInicial" => "202" "paginaFinal" => "209" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32278004" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0022347620314852" "estado" => "S300" "issn" => "00223476" ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0009" "etiqueta" => "[9]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "“Dual aetiology fatty liver disease”: a recently proposed term associated with potential pitfalls" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "C Moreno" 1 => "N Sheron" 2 => "D Tiniakos" 3 => "C Lackner" 4 => "P. Mathurin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jhep.2020.11.004" "Revista" => array:7 [ "tituloSerie" => "J Hepatol" "fecha" => "2021" "volumen" => "74" "numero" => "4" "paginaInicial" => "979" "paginaFinal" => "982" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33340582" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0010" "etiqueta" => "[10]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "What the new definition of MASLD left behind: dual etiology with viral hepatitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Y Fouad" 1 => "F Sanai" 2 => "M Alboraie" 3 => "M-H. Zheng" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:2 [ "tituloSerie" => "Clin Gastroenterol Hepatol" "fecha" => "2023" ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0011" "etiqueta" => "[11]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "From NAFLD to MAFLD: implications of a premature change in terminology" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "ZM Younossi" 1 => "ME Rinella" 2 => "AJ Sanyal" 3 => "SA Harrison" 4 => "EM Brunt" 5 => "Z Goodman" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1002/hep.31420" "Revista" => array:7 [ "tituloSerie" => "Hepatology" "fecha" => "2021" "volumen" => "73" "numero" => "3" "paginaInicial" => "1194" "paginaFinal" => "1198" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32544255" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0012" "etiqueta" => "[12]" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "How F to S turned the premature to be mature?" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Y Fouad" 1 => "M Alboraie" 2 => "M El-Shabrawi" 3 => "M-H. Zheng" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Hepatology" "fecha" => "2023" "volumen" => "10" "paginaInicial" => "1097" "itemHostRev" => array:3 [ "pii" => "S1548559521000902" "estado" => "S300" "issn" => "15485595" ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/16652681/0000002900000005/v1_202408300521/S1665268124003211/v1_202408300521/en/main.assets" "Apartado" => array:4 [ "identificador" => "82754" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Letters to the editor" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/16652681/0000002900000005/v1_202408300521/S1665268124003211/v1_202408300521/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1665268124003211?idApp=UINPBA00004N" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 16 | 4 | 20 |
| 2024 October | 163 | 27 | 190 |
| 2024 September | 124 | 19 | 143 |
| 2024 August | 87 | 19 | 106 |
| 2024 July | 128 | 27 | 155 |
